Patrys : Europe Grants Patent for Deoxymab 3E10

ASX & Media Release

Patrys Granted Deoxymab 3E10 Patent in Europe

• European patent granted for Patrys' novel Deoxymab 3E10 technology platform
• Patent covers the method of use of Deoxymab 3E10, including lead candidate PAT-DX1, as treatment for various cancers and malignancies
• Deoxymab 3E10 patents now secured in key markets including US, Europe, China and Japan
• The Deoxymab 3E10 platform has potential to revolutionise a broad range of cancer treatments and Patrys has made significant progress on pre-clinical and manufacturing development

Melbourne, Australia; 17 July 2019: Patrys Limited (ASX: PAB, "Patrys" or the "Company"), a therapeutic antibody development company, is pleased to announce that it has been granted a European patent (patent number: 2694555) titled "Cell-penetratinganti-DNA antibodies and uses thereof to inhibit DNA repair".

Patrys Chief Executive Officer and Managing Director, Dr. James Campbell said: "Patrys remains focused on building and maintaining patent protection across key jurisdictions. Europe represents an important region where a number of global pharmaceutical and biotechnology companies with innovative oncology divisions are based. Having secured patent protection in some of the world's largest pharmaceutical markets including USA, Europe, China and Japan, Patrys is well positioned to preserve future product sales in key target markets."

The patent covers the methods of using Patrys' novel Deoxymab 3E10 technology, including Patrys' lead candidate (PAT-DX1), as treatment for a broad range of cancers and malignancies including gliomas, metastases, breast, pancreatic, ovarian and prostate cancers and melanomas.

This patent substantially extends the intellectual property of the Company. The first patent in the 3E10 portfolio granted in the US in July 2017 and further patents were granted in Japan and China in July 2018. Patrys continues to focus on maintaining patent protection in major jurisdictions where future regulatory approvals and product sales are targeted, with more than 20 pending patent applications across 9 patent families.

Patrys continues to make significant progress with its PAT-DX1 program with recent pre-clinical data demonstrating PAT-DX1's ability to enhance efficacy of low dose radiation therapy in brain metastases. An additional pre-clinical study of PAT-DX1 and radiation to treat glioblastoma is targeted for completion in July 2019 with further studies (informed by the results of the current study) scheduled for completion late 3Q CY19 / early 4Q CY19.

-Ends-

1

To learn more please visit: www.patrys.com

For further information, please contact:

General enquiries	Media enquiries:
James Campbell	Kyahn Williamson
Chief Executive Officer	Buchan Consulting
P: [phone]	P: [phone]
[e-mail]	[e-mail]

About Patrys Limited

Based in Melbourne, Australia, Patrys (ASX:PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at www.patrys.com.

About Patrys' Deoxymab 3E10 platform - lead candidates PAT-DX1 and PAT-DX1-NP:

Deoxymab 3E10 is a DNA damage-repair antibody that was first identified in lupus. Of particular interest is that whilst most antibodies bind to cell surface markers, Deoxymab 3E10 penetrates into the cell nuclei and binds directly to DNA where it inhibits DNA repair processes and kills cells that have mutations or deficiencies in DNA repair mechanisms as found in various cancer cells. Deoxymab 3E10 has demonstrated single agent activity and has been shown to significantly enhance the efficacy of both chemotherapy and radiotherapy. Further, Deoxymab 3E10 can be conjugated to nanoparticles to target delivery of chemotherapeutics and imaging agents to tumours.

Patrys has developed a humanised form of Deoxymab 3E10, PAT-DX1 with improved activity over the original version of 3E10, and is progressing this, and a nanoparticle-conjugated form (PAT-DX1-NP) towards the clinic. In a range of pre-clinical cancer models PAT-DX1 has shown significant ability to kill cancer cells in cell models, human tumour explants, xenograft and orthotopic models. Treatment with PAT-DX1 has been shown to significantly improve survival in orthotopic models of both triple negative breast cancer brain metastases and glioblastoma. Significantly, PAT-DX1 has repeatedly been shown to be able to cross the blood brain barrier, a significant hurdle for therapeutics to combat brain cancers.

Patrys' rights to Deoxymab 3E10 are part of a worldwide license to develop and commercialise as anti-cancer and diagnostic agents a portfolio of novel anti-DNA antibodies and antibody fragments, variants and conjugates discovered at Yale University.

2